Connect with us

Business

IMF report in nutshell: Pakistan follows statist model | The Express Tribune

Published

on

IMF report in nutshell: Pakistan follows statist model | The Express Tribune


Statist economy, by restricting competition or picking up specific areas, allocates resources to protected sectors


ISLAMABAD:

By this time, many articles and commentaries have been published on the IMF report “Pakistan Governance and Corruption Diagnostic Assessment”. As already well understood before this report was issued, we do have systemic corruption and governance weaknesses that suppress investment, distort markets, undermine revenue collection, and perpetuate economic fragility.

We have been advocating that structural reforms, especially along the supply side, will unlock significant economic growth for Pakistan. This also resonated in the 5th Pakistan Prosperity Forum, which was themed on “Reforms for Growth”. Nevertheless, the report generated a stir. In this article, I will focus on what I believe is the main thrust of this report, building on a brief by the former chief economist, MA Zubair.

Fundamentally, the IMF report has concluded that we are running a statist economic model, which is now exhausted.

A statist economy is characterised by a state-corporate nexus, which thrives on thick protectionism, high tax rates and command and control. A statist economy is not a socialist economy; rather, it benefits a large section of the private sector, as argued by Khalil Ahmad in his thesis on the state elite.

A statist economy, by restricting competition or picking up specific sectors for government support, forcefully allocates resources to protected sectors. A large section of the private sector prospers due to its exclusive access to power, thus becoming an element and financier of the statist economy.

A statist economy has several tools available in its arsenal. It uses tax policy, tariffs, procurement, public spending, demand for credit, and state-run enterprises. None of these tools can be exercised without involving a private counterpart. Tax exemptions benefit certain sectors and firms; tariff protections provide advantages to a few at the cost of many; government procurement rules limit competition; development spending awards go to contractors; most of the banking credit goes to the federal government; and state-owned enterprises command half of the nation’s assets.

The IMF report synthesises these otherwise well-known characteristics of our economic model systematically, while providing evidence and data. In a way, this is a continuation of a report that UNDP published in 2021, which quantified ‘elite capture’ by measuring the cost of tax, privileges and tariff exemptions, while reminding us of the work of Dr Ishrat Husain on elitist state, around 25 years ago.

All exemptions granted, all procurement, and all transactions by state-owned enterprises have complete legal, legislative and judicial cover. None of these can be considered corruption or illegal in a formal sense. However, it is obvious that these systematic manipulations and intended distortions unlevel the playing field, erode opportunities, and retards economic growth. The IMF report also puts a number on it – a potential of 5% to 6% additional growth over the next five years.

Pakistan needs to shift from a statist economy to a market economy, which celebrates wealth creation under a responsible and limited state. Under an open political system, this culture will help wealth distribution, as private firms will compete for their market share without any restrictions.

A market economy is designed by rules and regulations. Voluntary exchange between individuals and firms is fundamentally driven by mutual trust. In the absence of these formal and informal institutions, exchange breaks down, and the market ceases to exist.

If you know that a local shop or a brand has deceptively sold you inferior quality goods, you are unlikely to make another purchase. If this information becomes widely known, the business closes down. This fatal discipline of the market keeps a check on producers and other market participants.

In contrast to a statist economy, a market economy, while far from perfection, thrives on economic freedom, but then, as Nadeemul Haque asserts, where are these markets? These markets, as we observe today, have a lot of friction and sludge. While we do face macroeconomic problems, these frictions are created by institutions and institutional practices, which keep increasing transaction costs.

Business groups oppose tariff liberalisation because they rightly see cost disadvantages in the form of high tax rates and high energy costs. They need the government to compensate for these advantages through tariff walls. Now these walls are gone, or they will be – brick by brick – there is a lot of resistance and frustration.

The solution does not lie in reversing tariff reforms; the solution lies in doing all other actions, where the government is seriously lacking. These other actions must be led by tax rates in one big move, especially now that the government is confident about deterrence and enforcement. The second major move must be rewriting the regulatory playbook. There are other actions, such as privatisation and spending cuts, which must be taken too.

The real economic transformation will occur when we begin our journey from a statist economy to a market economy. But the window is very small and is narrowing down.

The writer is the founder and CEO of Policy Research Institute of Market Economy, an independent economic think tank



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Apple names new boss to replace Tim Cook after 15 years

Published

on

Apple names new boss to replace Tim Cook after 15 years



John Ternus will take over running the technology giant as Cook steps up to become executive chairman.



Source link

Continue Reading

Business

SBP receives final $1bn from Saudi Arabia, bringing total deposit reaches $3bn – SUCH TV

Published

on

SBP receives final bn from Saudi Arabia, bringing total deposit reaches bn – SUCH TV



The State Bank of Pakistan (SBP) has received $1 billion from the Ministry of Finance of the Kingdom of Saudi Arabia, marking the second tranche of a $3 billion deposit agreed recently, the central bank said on Tuesday.

According to the statement issued by the central bank, the second tranche was received with a value date of April 20, 2026.

The first tranche of $2 billion had already been received on April 15, 2026, bringing the total inflows under the arrangement to $3 billion.

The development comes days after Prime Minister Shehbaz Sharif’s visit to Saudi Arabia, where he engaged in diplomatic efforts aimed at promoting regional peace.

During his visit, the premier met Crown Prince Mohammed bin Salman in Jeddah and expressed appreciation for the Kingdom’s continued support for Pakistan’s economic stability. He also conveyed solidarity with Saudi Arabia in light of recent regional developments.

Earlier on April 16, Finance Minister Muhammad Aurangzeb had announced that Saudi Arabia would provide $3 billion in additional financial support, with disbursement expected shortly.

He also noted that Riyadh had extended the tenure of its existing $5 billion deposit, removing the earlier annual rollover requirement.

The Saudi funding has strengthened Pakistan’s external position as it repaid $2 billion in debt to the United Arab Emirates (UAE).

The amount was kept with the central banks as a safe deposit.

Saudi Arabia has been a key financial partner for Pakistan, having provided support packages during previous economic challenges, including a $6 billion assistance programme in 2018 comprising deposits and oil facility arrangements.



Source link

Continue Reading

Business

How Trump’s psychedelics executive order could unlock stalled cannabis reform

Published

on

How Trump’s psychedelics executive order could unlock stalled cannabis reform


Advocates attend a news conference about the “impact of incarcerating those charged with marijuana-related offenses,” and policy reform ideas, outside the U.S. Capitol on April 20, 2026.

Tom Williams | CQ-Roll Call, Inc. | Getty Images

A White House executive order on psychedelics, signed by President Donald Trump on Saturday, aims to speed up research on drugs like psilocybin, MDMA and ibogaine, helping to legitimize an industry that’s long lived largely underground.

But it also raises a broader question: Will psychedelics fall victim, like cannabis has, to a slow-moving federal process?

The latest executive order comes roughly four months after an effort by President Trump to reschedule cannabis, opening the door to greater research and investment opportunities. But since that directive, progress to reclassify cannabis has largely stalled, with the Drug Enforcement Administration review still ongoing and no final decision on moving marijuana from Schedule I to the lesser Schedule III.

The delay reflects how drug policy often slows once it enters interagency review, where scientific evaluation, legal standards and politics meet.

“The process has certainly been slow and frustrating for stakeholders when you consider they have spent decades fighting marijuana’s outrageous 1970s-era misclassification,” said Shawn Hauser, partner at cannabis law firm Vicente LLP.

Vicente LLP also serves as legal counsel for the National Compassionate Care Council, or NCCC, a coalition of health-care stakeholders focused on evidence-based cannabis policy.

The psychedelics order, however, focuses on research acceleration rather than legalization. It directs agencies like the U.S. Food and Drug Administration to expand clinical trials and “Right to Try” access for patients with serious mental health conditions, while leaving drug scheduling unchanged.

AtaiBeckley is among a number of psychedelics-focused drug developers whose stock is rallying since the order was signed over the weekend, up roughly 25% Monday. Several smaller-market cap stocks also jumped, including Compass Pathways, Definium Therapeutics and U.S.-listed shares of Cybin.

Hauser said the recent psychedelics order reflects a broader shift in Washington toward a medical-first framework and could mark a path forward for cannabis rescheduling.

“The science-, patient-, health-care-first approach is winning in Washington right now,” she said.

“The psychedelic pathway — built on physician-led protocols, clinical research and compassionate use frameworks — is actually a model cannabis advocates should be studying and adopting more aggressively,” Hauser said.

Safety first

Trump’s psychedelics measure has drawn particular attention for its inclusion of ibogaine, a powerful, naturally occurring psychoactive compound with long-standing safety concerns.

The drug is being studied for its applications with post-traumatic stress disorder, depression and addiction, but cardiac risks flagged by Nora Volkow of the National Institute on Drug Abuse remain a major barrier.

That tension is heightened by the expansion of “Right to Try” access, a federal law allowing patients diagnosed with life-threatening diseases or conditions to try experimental drugs when no other treatments work. This distinction typically applies only after Phase I trials are successful.

Ibogaine has struggled to meet that criteria, since most of the research into the drug has been conducted outside the U.S.

Psychedelic industry leaders say the order is meaningful, but the full impacts are still unknown until implementation catches up to prove scientific value.

“The opportunity now is not hype, it’s execution: rigorous science, disciplined safety standards, physician-led protocols and real-world outcome data,” said Tom Feegel, CEO of clinical neurohealth center Beond.

Beond, based in Cancun, Mexico, specializes in ibogaine therapy.

Feegel added that while the executive order signals legitimacy at the highest level of government, the next phase is critical.

Psychedelics still lack a commercial market, though clinical-stage developers, like AtaiBeckley, Compass and GH Research, are emerging. Many prioritize research around less controversial psychedelics like psilocybin and MDMA derivatives for mental health treatment.

U.S. states have been weighing the space, too. Colorado advanced regulated psychedelic access for its residents in 2022, while a Massachusetts ballot measure failed in 2024 with 56% of voters rejecting the access.

Cannabis, by contract, already has a multibillion-dollar adult-use industry across dozens of states, giving it a significant head start even as federal rescheduling remains unresolved.

Hauser argued the two industries are ultimately reinforcing one another.

“The two regulatory tracks aren’t in conflict,” she said. “Both are advancing the broader legitimacy of plant-based alternative medicines, and the infrastructure being built for one will inevitably support the other.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Trending